Replies to post #18053 on RespireRx Pharmaceuticals Inc (RSPI)

[Aiming4]

myostrain - I doubt NeuroChemical Modulation will get anything out of the ordinary in terms of royalties from Cortex.

But if RD ends up being anywhere near as big as its potential, even a small % of that revenue stream, especially for a small company like NM, will be very significant.

Even multiplied moreso if NM has a small share structure.

We'll have to wait and see if there's any investing opportunity in the new company, but we should at least be first in line to be aware of the potential and maybe get in on the ground floor.

[gfp927z]

Myostrain, Here are some of Neuro's comments from a while back concerning Greer's likely RD related milestones / royalties -

>>> Greer discovered that AMPA modulators could impact RD via the Pre-Botzinger complex, and thus patented the use of AMPA modulation for that purpose. Cortex owns CX717, but would not be able to market it for the RD use without a license from U.Alberta. They now have both the molecule, and an exclusive license for the RD use. I recall a small upfront payment ($250K?), I'm sure there will be milestones and small (typically 2-3%) royalties.

NeuroInvestment <<<